CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:In Vitro Models to Compare the Duration of Action of New Therapeutic Scaffolds and Drug Eluting Medical Devices.
In Vitro Models to Compare the Duration of Action of New Therapeutic Scaffolds and Drug Eluting Medical Devices.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
局部疗法正在开发中,用于靶向脑肿瘤和癌症干细胞,以及非脑肿瘤,因为存在显著的运输屏障,阻碍药物在疾病部位充分积累。对于化疗药物,局部递送在脑肿瘤的临床实践中已是成熟做法。对于免疫治疗应用,局部疗法可包括递送免疫细胞衔接器、过继性细胞疗法或联合疗法,以促进适应性反应。局部疗法的作用持续时间很重要,需要延长并通过筛选来鉴定单次或最少给药即可有效的制剂。为此,本章讨论了三维嵌入式多细胞球体模型的开发,用于实时追踪球体杀伤,并利用新型治疗支架和药物洗脱医疗器械筛选局部 T 细胞衔接器的延长作用持续时间。
Local therapies are in development for targeting of brain tumors and cancer stem cells, as well as non-brain tumors, due to significant transport barriers that hinder sufficient drug accumulation at the disease site. For chemotherapeutics, local delivery is already a well-established practice in the clinic for brain tumors. For immunotherapy applications, local therapies can include the delivery of immune cell engagers, adoptive cell therapies, or combination therapies to encourage adaptive responses.
The duration of action of local therapies is important to extend and screen to identify efficacious formulations with a single or minimal administration. To this end, this chapter discusses the development of three-dimensional embedded multi-cellular spheroid models to track spheroid killing in real time and to screen the extended duration of action of local T cell engagers with new therapeutic scaffolds and drug eluting medical devices.
MEMBER ACCOUNT
登录成功会直接打开下一页。